Abstract
Atherosclerosis is considered an inflammatory disease. T-cells, macrophages, and mast cells infiltrate atherosclerotic plaques and platelets play an essential role releasing inflammatory mediators that stimulate plaque progression. This is important in acute coronary syndromes but it is also the mechanism involved in plaque progresion and endothelial dysfunction. Antiplatelet drugs exert their effects not only by inhibition of platelet aggregation but also through their antiinflammatory effect. Aspirin, thyenopiridines and GPIIb/IIIa inhibitors have antiinflammatory properties that involve different mechanisms of action, especially related to the blockade of platelet activation and platelet-leukocyte interactions. Testing platelet function in addition to assessing levels of inflammatory markers, and not only the risk of bleeding, could help in decision-making to balance the risk-benefit of anti-thrombotic treatment. Different clinical settings are associated with variable inflammatory states, and this could be, in part, responsible for variable response to treatment.
Keywords: Atherosclerosis, inflammation, antiplatelet, anti-inflammatory, T-cells, macrophages, mast cells, plaque, endothelial dysfunction, platelet activation
Current Pharmaceutical Design
Title:Anti-Inflammatory Effects of Anti-Platelet Treatment in Atherosclerosis
Volume: 18 Issue: 28
Author(s): H. Cohen Arazi and J.J. Badimon
Affiliation:
Keywords: Atherosclerosis, inflammation, antiplatelet, anti-inflammatory, T-cells, macrophages, mast cells, plaque, endothelial dysfunction, platelet activation
Abstract: Atherosclerosis is considered an inflammatory disease. T-cells, macrophages, and mast cells infiltrate atherosclerotic plaques and platelets play an essential role releasing inflammatory mediators that stimulate plaque progression. This is important in acute coronary syndromes but it is also the mechanism involved in plaque progresion and endothelial dysfunction. Antiplatelet drugs exert their effects not only by inhibition of platelet aggregation but also through their antiinflammatory effect. Aspirin, thyenopiridines and GPIIb/IIIa inhibitors have antiinflammatory properties that involve different mechanisms of action, especially related to the blockade of platelet activation and platelet-leukocyte interactions. Testing platelet function in addition to assessing levels of inflammatory markers, and not only the risk of bleeding, could help in decision-making to balance the risk-benefit of anti-thrombotic treatment. Different clinical settings are associated with variable inflammatory states, and this could be, in part, responsible for variable response to treatment.
Export Options
About this article
Cite this article as:
Cohen Arazi H. and Badimon J.J., Anti-Inflammatory Effects of Anti-Platelet Treatment in Atherosclerosis, Current Pharmaceutical Design 2012; 18 (28) . https://dx.doi.org/10.2174/138161212802481264
DOI https://dx.doi.org/10.2174/138161212802481264 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolic Syndrome and Psychiatric Practice: Clinical and Management Issues
Current Psychiatry Reviews Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Osteoarthritis - Current Insights in Pathogenesis, Diagnosis and Treatment
Current Rheumatology Reviews Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Editorial (Thematic Issue: Skin Inflammation and Inflammaging)
Inflammation & Allergy - Drug Targets (Discontinued) Global View on Alzheimer’s Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer’s Disease and Diabetes Mellitus
Current Alzheimer Research Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem
Current Neuropharmacology Microvascular Endothelial Dysfunction in Obesity and Hypertension
Current Pharmaceutical Design Clinical Application of Surface-Linked Liposomal Antigens
Mini-Reviews in Medicinal Chemistry Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine Syntheses of Ethyl Pyruvate’s Bioisosteres Inhibiting Inducible Nitric Oxide Production in Lipopolysaccharide-induced BV2 Cells
Letters in Drug Design & Discovery Safer Vectors for Gene Therapy of Primary Immunodeficiencies
Current Gene Therapy Antinflammatory Effects of Allergen Immunotherapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy
Mini-Reviews in Medicinal Chemistry The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds
Current Drug Metabolism Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Cold-Adapted Esterases and Lipases: A Biodiversity Still Under-Exploited
Current Chemical Biology Biotransformations of Prenylated Hop Flavonoids for Drug Discovery and Production
Current Drug Metabolism Glycyrrhetinic Acid and Its Derivatives: Anti-Cancer and Cancer Chemopreventive Properties, Mechanisms of Action and Structure- Cytotoxic Activity Relationship
Current Medicinal Chemistry Labelling and Tracking of Human Mesenchymal Stromal Cells in Preclinical Studies and Large Animal Models of Degenerative Diseases
Current Stem Cell Research & Therapy